Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881954 | 0.92 | HPGD (0.72) | KMT2AALDH1A1MEN1HPGDMAPT | |
| SCHEMBL4784539 | 0.81 | MAPT (0.80) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL4784250 | 0.81 | MAPT (0.70) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL12846033 | 0.81 | KMT2A (0.71) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL4732936 | 0.80 | MAPT (0.69) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL3351099 | 0.79 | PKM (0.48) | KMT2AALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL14433749 | 0.79 | HSD17B2 (0.66) | — | |
| SCHEMBL21935233 | 0.79 | HSD17B2 (0.53) | KMT2AHPGDMAPTHSD17B10 | |
| SCHEMBL3021651 | 0.78 | ALDH1A1 (0.66) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 | |
| SCHEMBL6353681 | 0.78 | KMT2A (0.64) | KMT2AALDH1A1MEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053995-A1 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-03-03 | — | — | US | claimed |
| WO-2008061247-A2 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS | THE REGENT OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-22 | — | — | WO | claimed |
| US-9316633-B2 | Methods for identifying inhibitors of solute transporters | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-19 | — | — | US | disclosed |
| US-20110053995-A1 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053995-A1 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053995-A1 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100190796-A1 | METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2008061247-A2 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS | THE REGENT OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008061247-A2 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS | THE REGENT OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190796-A1 | METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS | SLC2A1, SLC2A3, SLC2A8 | KMT2A 4412/4885ALDH1A1 3404/4885MEN1 1626/4885 |
| US-20110053995-A1 | BENZENESULFONANILIDE COMPOUND INHIBITORS OF UREA TRANSPORTERS | SLC14A1, SLC2A1, SLC2A4 | KMT2A 4539/4885ALDH1A1 1500/4885MEN1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.